Ep. 177 Latest Approaches to Treat High-Risk NMIBC with Dr. Ashish Kamat

In this episode of the BackTable Urology Podcast, Dr. Ashish Kamat discusses contemporary management of high-risk, non-muscle-invasive bladder cancer (NMIBC) and his thoughts into the future of this arena. --- CHECK OUT OUR SPONSOR Siemens Healthineers Theranostics https://www.siemens-healthineers.com/en-us/clinical-specialities/theranostics --- SYNPOSIS Dr. Kamat explores the evolving role of BCG and potential alternative therapies such as gemcitabine and docetaxel. He also covers effective clinical management, emerging clinical trials, and nuanced decision-making principles for radical cystectomy. Finally, the conversation touches on Dr. Kamat’s expert insights regarding the future of NMIBC management, including predictive biomarkers and personalized medicine. --- TIMESTAMPS 00:00 - Introduction 03:56 - Initial Diagnosis and Workup 12:22 - High-Grade Bladder Cancer 22:37 - BCG and Alternative Treatments 31:30 - BCG Unresponsive Disease 36:56 - Novel Intravesical and Systemic Therapies 46:45 - Future Directions --- RESOURCES Related BackTable episodes: https://www.backtable.com/shows/urology/podcasts/64/management-of-bcg-refractory-nmibc https://www.backtable.com/shows/urology/podcasts/157/the-bladder-cancer-matters-podcast https://www.backtable.com/shows/urology/podcasts/103/adjuvant-therapy-for-high-risk-bladder-cancer

There are no comments yet.

Please log in to write the first comment.